1
|
Oxidised Low-Density Lipoprotein-Induced Platelet Hyperactivity—Receptors and Signalling Mechanisms. Int J Mol Sci 2022; 23:ijms23169199. [PMID: 36012465 PMCID: PMC9409144 DOI: 10.3390/ijms23169199] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2022] [Revised: 07/26/2022] [Accepted: 08/09/2022] [Indexed: 11/17/2022] Open
Abstract
Dyslipidaemia leads to proatherogenic oxidative lipid stress that promotes vascular inflammation and thrombosis, the pathologies that underpin myocardial infarction, stroke, and deep vein thrombosis. These prothrombotic states are driven, at least in part, by platelet hyperactivity, and they are concurrent with the appearancxe of oxidatively modified low-density lipoproteins (LDL) in the circulation. Modified LDL are heterogenous in nature but, in a general sense, constitute a prototype circulating transporter for a plethora of oxidised lipid epitopes that act as danger-associated molecular patterns. It is well-established that oxidatively modified LDL promote platelet activation and arterial thrombosis through a number of constitutively expressed scavenger receptors, which transduce atherogenic lipid stress to a complex array of proactivatory signalling pathways in the platelets. Stimulation of these signalling events underlie the ability of modified LDL to induce platelet activation and blunt platelet inhibitory pathways, as well as promote platelet-mediated coagulation. Accumulating evidence from patients at risk of arterial thrombosis and experimental animal models of disease suggest that oxidised LDL represents a tangible link between the dyslipidaemic environment and increased platelet activation. The aim of this review is to summarise recent advances in our understanding of the pro-thrombotic signalling events induced in platelets by modified LDL ligation, describe the contribution of individual platelet scavenger receptors, and highlight potential future challenges of targeting these pathways.
Collapse
|
2
|
Zheng Y, Gao W, Zhang Q, Cheng X, Liu Y, Qi Z, Li T. Ferroptosis and Autophagy-Related Genes in the Pathogenesis of Ischemic Cardiomyopathy. Front Cardiovasc Med 2022; 9:906753. [PMID: 35845045 PMCID: PMC9279674 DOI: 10.3389/fcvm.2022.906753] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2022] [Accepted: 05/19/2022] [Indexed: 11/13/2022] Open
Abstract
Background Obesity plays an important role in type 2 diabetes mellitus (T2DM) and myocardial infarction (MI). Ferroptosis and ferritinophagy are related to metabolic pathways, such as fatty acid metabolism and mitochondrial respiration. We aimed to investigate the ferroptosis- and autophagy-related differentially expressed genes (DEGs) that might be potential targets for MI progression. Methods GSE116250 was analyzed to obtain DEGs. A Venn diagram was used to obtain the overlapping ferroptosis- and autophagy-related DEGs. The enrichment pathway analysis was performed and the hub genes were obtained. Pivotal miRNAs, transcription factors, and drugs with the hub genes interactions were also predicted. The MI mice model was constructed, and qPCR analysis and single-cell sequencing were used to validate the hub genes. Results Utilizing the limma package and the Venn diagram, 26 ferroptosis-related and 29 autophagy-related DEGs were obtained. The list of ferroptosis-related DEGs was analyzed, which were involved in the cellular response to a toxic substance, cellular oxidant detoxification, and the IL-17 signaling pathway. The list of autophagy-related DEGs was involved in the regulation of autophagy, the regulation of JAK-STAT signaling pathway, and the regulation of MAPK cascade. In the protein-protein interaction network, the hub DEGs, such as IL-6, PTGS2, JUN, NQO1, NOS3, LEPR, NAMPT, CDKN2A, CDKN1A, and Snai1, were obtained. After validation using qPCR analysis in the MI mice model and single-cell sequencing, the 10 hub genes can be the potential targets for MI deterioration. Conclusion The screened hub genes, IL-6, PTGS2, JUN, NQO1, NOS3, LEPR, NAMPT, CDKN2A, CDKN1A, and Snai1, may be therapeutic targets for patients with MI and may prevent adverse cardiovascular events.
Collapse
Affiliation(s)
- Yue Zheng
- School of Medicine, Nankai University, Tianjin, China
- Department of Heart Center, The Third Central Hospital of Tianjin, Tianjin, China
- Nankai University Affiliated Third Center Hospital, Nankai University, Tianjin, China
- Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Tianjin, China
- Artificial Cell Engineering Technology Research Center, Tianjin, China
| | - Wenqing Gao
- School of Medicine, Nankai University, Tianjin, China
- Department of Heart Center, The Third Central Hospital of Tianjin, Tianjin, China
- Nankai University Affiliated Third Center Hospital, Nankai University, Tianjin, China
- Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Tianjin, China
- Artificial Cell Engineering Technology Research Center, Tianjin, China
| | - Qiang Zhang
- School of Medicine, Nankai University, Tianjin, China
- Department of Heart Center, The Third Central Hospital of Tianjin, Tianjin, China
- Nankai University Affiliated Third Center Hospital, Nankai University, Tianjin, China
- Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Tianjin, China
- Artificial Cell Engineering Technology Research Center, Tianjin, China
| | - Xian Cheng
- School of Medicine, Nankai University, Tianjin, China
- Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Tianjin, China
- Artificial Cell Engineering Technology Research Center, Tianjin, China
- Department of Heart Center, The Third Central Clinical College of Tianjin Medical University, Tianjin, China
| | - Yanwu Liu
- School of Medicine, Nankai University, Tianjin, China
- Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Tianjin, China
- Artificial Cell Engineering Technology Research Center, Tianjin, China
- Department of Heart Center, The Third Central Clinical College of Tianjin Medical University, Tianjin, China
| | - Zhenchang Qi
- School of Medicine, Nankai University, Tianjin, China
- Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Tianjin, China
- Artificial Cell Engineering Technology Research Center, Tianjin, China
- Department of Heart Center, The Third Central Clinical College of Tianjin Medical University, Tianjin, China
| | - Tong Li
- School of Medicine, Nankai University, Tianjin, China
- Department of Heart Center, The Third Central Hospital of Tianjin, Tianjin, China
- Nankai University Affiliated Third Center Hospital, Nankai University, Tianjin, China
- Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Tianjin, China
- Artificial Cell Engineering Technology Research Center, Tianjin, China
- Department of Heart Center, The Third Central Clinical College of Tianjin Medical University, Tianjin, China
- *Correspondence: Tong Li,
| |
Collapse
|
3
|
Tang Y, Liu W, Wang W, Fidler T, Woods B, Levine RL, Tall AR, Wang N. Inhibition of JAK2 Suppresses Myelopoiesis and Atherosclerosis in Apoe -/- Mice. Cardiovasc Drugs Ther 2020; 34:145-152. [PMID: 32086626 PMCID: PMC7125070 DOI: 10.1007/s10557-020-06943-9] [Citation(s) in RCA: 29] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
OBJECTIVE Increased myelopoiesis has been linked to risk of atherosclerotic cardiovascular disease (ACD). Excessive myelopoiesis can be driven by dyslipidemia and cholesterol accumulation in hematopoietic stem and progenitor cells (HSPC) and may involve increased signaling via Janus kinase 2 (JAK2). Constitutively activating JAK2 mutants drive biased myelopoiesis and promote development of myeloproliferative neoplasms (MPN) or clonal hematopoiesis, conditions associated with increased risk of ACD. JAK2 inhibitors have been developed as a therapy for MPNs. The potential for JAK2 inhibitors to protect against atherosclerosis has not been tested. We therefore assessed the impact of JAK2 inhibition on atherogenesis. METHODS A selective JAK2 inhibitor TG101348 (fedratinib) or vehicle was given to high-fat high-cholesterol Western diet (WD)-fed wild-type (WT) or Apoe-/- mice. Hematopoietic cell profiles, cell proliferation, and atherosclerosis in WT or Apoe-/- mice were assessed. RESULTS TG101348 selectively reversed neutrophilia, monocytosis, HSPC, and granulocyte-macrophage progenitor (GMP) expansion in Apoe-/- mice with decreased cellular phosphorylated STAT5 and ERK1/2 and reduced cell cycling and BrdU incorporation in HSPCs, indicating inhibition of JAK/STAT signaling and cell proliferation. Ten-week WD feeding allowed the development of marked aortic atherosclerosis in Apoe-/- mice which was substantially reduced by TG101348. CONCLUSIONS Selective JAK2 inhibition reduces atherogenesis by suppressing excessive myelopoiesis in hypercholesterolemic Apoe-/- mice. These findings suggest selective JAK2 inhibition as a potential therapeutic approach to decrease ACD risk in patients with increased myelopoiesis and leukocytosis.
Collapse
Affiliation(s)
- Yang Tang
- Division of Molecular Medicine, Department of Medicine, Columbia University Medical Center, 630 W. 168th Street, New York, NY, 10032, USA.,Department of Hematology, The First Hospital of Jilin University, Changchun, People's Republic of China
| | - Wenli Liu
- Division of Molecular Medicine, Department of Medicine, Columbia University Medical Center, 630 W. 168th Street, New York, NY, 10032, USA
| | - Wei Wang
- Division of Molecular Medicine, Department of Medicine, Columbia University Medical Center, 630 W. 168th Street, New York, NY, 10032, USA
| | - Trevor Fidler
- Division of Molecular Medicine, Department of Medicine, Columbia University Medical Center, 630 W. 168th Street, New York, NY, 10032, USA
| | - Britany Woods
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.,Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Ross L Levine
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.,Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Alan R Tall
- Division of Molecular Medicine, Department of Medicine, Columbia University Medical Center, 630 W. 168th Street, New York, NY, 10032, USA
| | - Nan Wang
- Division of Molecular Medicine, Department of Medicine, Columbia University Medical Center, 630 W. 168th Street, New York, NY, 10032, USA.
| |
Collapse
|
4
|
Martínez-Hervás S, Sánchez-García V, Herrero-Cervera A, Vinué Á, Real JT, Ascaso JF, Burks DJ, González-Navarro H. Type 1 diabetic mellitus patients with increased atherosclerosis risk display decreased CDKN2A/2B/2BAS gene expression in leukocytes. J Transl Med 2019; 17:222. [PMID: 31299986 PMCID: PMC6626385 DOI: 10.1186/s12967-019-1977-1] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2019] [Accepted: 07/08/2019] [Indexed: 12/12/2022] Open
Abstract
Background Type 1 diabetes mellitus (T1DM) patients display increased risk of cardiovascular disease (CVD) and are characterized by a diminished regulatory T (Treg) cell content or function. Previous studies have shown an association between decreased CDKN2A/2B/2BAS gene expression and enhanced CVD. In the present study the potential relationship between CDKN2A/2B/2BAS gene expression, immune cell dysfunction and increased cardiovascular risk in T1DM patients was explored. Methods A cross-sectional study was performed in 90 subjects divided into controls and T1DM patients. Circulating leukocyte subpopulations analysis by flow cytometry, expression studies on peripheral blood mononuclear cell by qPCR and western blot and correlation studies were performed in both groups of subjects. Results Analysis indicated that, consistent with the described T cell dysfunction, T1DM subjects showed decreased circulating CD4+CD25+CD127− Treg cells. In addition, T1DM subjects had lower mRNA levels of the transcription factors FOXP3 and RORC and lower levels of IL2 and IL6 which are involved in Treg and Th17 cell differentiation, respectively. T1DM patients also exhibited decreased mRNA levels of CDKN2A (variant 1 p16Ink4a), CDKN2A (p14Arf,variant 4), CDKN2B (p15Ink4b) and CDKN2BAS compared with controls. Notably, T1DM patients had augmented pro-atherogenic CD14++CD16+-monocytes, which predict cardiovascular acute events and enhanced common carotid intima-media thickness (CC-IMT). Conclusions Decreased expression of CDKN2A/2B/2BAS in leukocytes associates with increased CC-IMT atherosclerosis surrogate marker and proatherogenic CD14++CD16+ monocytes in T1DM patients. These results suggest a potential role of CDKN2A/2B/2BAS genes in CVD risk in T1DM. Electronic supplementary material The online version of this article (10.1186/s12967-019-1977-1) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Sergio Martínez-Hervás
- Endocrinology and Nutrition Department Hospital Clínico Universitario. Department of Medicine, University of Valencia, 46010, Valencia, Spain.,INCLIVA Institute of Health Research, Avda. Menéndez Pelayo, 4, 46010, Valencia, Spain.,CIBER Diabetes and Associated Metabolic Diseases (CIBERDEM), 28029, Madrid, Spain
| | | | | | - Ángela Vinué
- INCLIVA Institute of Health Research, Avda. Menéndez Pelayo, 4, 46010, Valencia, Spain
| | - José Tomás Real
- Endocrinology and Nutrition Department Hospital Clínico Universitario. Department of Medicine, University of Valencia, 46010, Valencia, Spain.,INCLIVA Institute of Health Research, Avda. Menéndez Pelayo, 4, 46010, Valencia, Spain.,CIBER Diabetes and Associated Metabolic Diseases (CIBERDEM), 28029, Madrid, Spain
| | - Juan F Ascaso
- Endocrinology and Nutrition Department Hospital Clínico Universitario. Department of Medicine, University of Valencia, 46010, Valencia, Spain.,INCLIVA Institute of Health Research, Avda. Menéndez Pelayo, 4, 46010, Valencia, Spain.,CIBER Diabetes and Associated Metabolic Diseases (CIBERDEM), 28029, Madrid, Spain
| | - Deborah Jane Burks
- CIBER Diabetes and Associated Metabolic Diseases (CIBERDEM), 28029, Madrid, Spain.,Príncipe Felipe Research Center (CIPF), 46012, Valencia, Spain
| | - Herminia González-Navarro
- INCLIVA Institute of Health Research, Avda. Menéndez Pelayo, 4, 46010, Valencia, Spain. .,CIBER Diabetes and Associated Metabolic Diseases (CIBERDEM), 28029, Madrid, Spain. .,Department of Didactics of Experimental and Social Sciences, University of Valencia, 46010, Valencia, Spain.
| |
Collapse
|
5
|
Mucke HA. Drug Repurposing Patent Applications October–December 2018. Assay Drug Dev Technol 2019; 17:249-254. [DOI: 10.1089/adt.2019.937] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
6
|
Changes in CDKN2A/2B expression associate with T-cell phenotype modulation in atherosclerosis and type 2 diabetes mellitus. Transl Res 2019; 203:31-48. [PMID: 30176239 DOI: 10.1016/j.trsl.2018.08.003] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/23/2018] [Revised: 08/03/2018] [Accepted: 08/07/2018] [Indexed: 12/12/2022]
Abstract
Previous studies indicate a role of CDKN2A/2B/2BAS genes in atherosclerosis and type 2 diabetes mellitus (T2DM). Progression of these diseases is accompanied by T-cell imbalance and chronic inflammation. Our main objective was to investigate a potential association between CDKN2A/2B/2BAS gene expression and T cell phenotype in T2DM and coronary artery disease (CAD) in humans, and to explore the therapeutic potential of these genes to restore immune cell homeostasis and disease progression. Reduced mRNA levels of CDKN2A (p16Ink4a), CDKN2B (p15Ink4b), and CDKN2BAS were observed in human T2DM and T2DM-CAD subjects compared with controls. Protein levels of p16Ink4a and p15Ink4b were also diminished in T2DM-CAD patients while CDK4 levels, the main target of p16Ink4a and p15Ink4b, were augmented in T2DM and T2DM-CAD subjects. Both patient groups displayed higher activated CD3+CD69+ T cells and proatherogenic CD14++CD16+ monocytes, while CD4+CD25+CD127 regulatory T (Treg cells) cells were decreased. Treatment of primary human lymphocytes with PD0332991, a p16Ink4a/p15Ink4b mimetic drug and a proven CDK4 inhibitor, increased Treg cells and the levels of activated transcription factor phosphoSTAT5. In vivo PD0332991 treatment of atherosclerotic apoE-/- mice and insulin resistant apoE-/-Irs2+/- mice augmented Foxp3-expressing Treg cells and decreased lesion size. Thus, atherosclerosis complications in T2DM associate with altered immune cell homeostasis, diminished CDKN2A/2B/2BAS expression, and increased CDK4 levels. The present study also suggests that the treatment with drugs that mimic CDKN2A/2B genes could potential be considered as a promising therapy to delay atherosclerosis.
Collapse
|
7
|
Yang J, Gu L, Guo X, Huang J, Chen Z, Huang G, Kang Y, Zhang X, Long J, Su L. LncRNA ANRIL Expression and ANRIL Gene Polymorphisms Contribute to the Risk of Ischemic Stroke in the Chinese Han Population. Cell Mol Neurobiol 2018; 38:1253-1269. [DOI: 10.1007/s10571-018-0593-6] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2018] [Accepted: 05/23/2018] [Indexed: 12/13/2022]
|
8
|
Arbiol-Roca A, Padró-Miquel A, Vidal-Alabró A, Hueso M, Fontova P, Bestard O, Rama I, Torras J, Grinyó JM, Alía-Ramos P, Cruzado JM, Lloberas N. ANRIL as a genetic marker for cardiovascular events in renal transplant patients - an observational follow-up cohort study. Transpl Int 2018; 31:1018-1027. [PMID: 29722077 DOI: 10.1111/tri.13276] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2017] [Revised: 12/18/2017] [Accepted: 04/20/2018] [Indexed: 01/09/2023]
Abstract
Cardiovascular disease is the leading cause of morbidity and mortality in kidney transplant recipients. Several single-nucleotide polymorphisms (SNPs) in the ANRIL gene pathway have been associated with cardiovascular events (CE). The main objective was to ascertain whether ANRIL (rs10757278) and CARD8 (rs2043211) SNPs could mediate susceptibility to CE. This was an observational follow-up cohort study of renal transplant recipients at Bellvitge University Hospital (Barcelona) from 2000 to 2014. A total of 505 recipients were followed up until achievement of a CE. Patients who did not achieve the endpoint were followed up until graft loss, lost to follow-up or death. Survival analysis was used to ascertain association between genetic markers, clinical data, and outcome. Fifty-three patients suffered a CE after renal transplantation. Results showed a significant association between ANRIL SNP and CE. Homozygous GG for the risk allele showed higher risk for CE than A carriers for the protective allele [HR = 2.93(1.69-5.11), P < 0.0001]. This effect was maintained when it was analyzed in combination with CARD8, suggesting that CARD8 SNP could play a role in the ANRIL mechanism. However, our study does not clarify the molecular mechanism for the CARD8 SNP regulation by ANRIL. ANRIL SNP may predispose to the development of CE after successful kidney transplantation.
Collapse
Affiliation(s)
- Ariadna Arbiol-Roca
- Biochemistry Department, IDIBELL, Hospital Universitari de Bellvitge, Barcelona, Spain
- PhD student at Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - Ariadna Padró-Miquel
- Biochemistry Department, IDIBELL, Hospital Universitari de Bellvitge, Barcelona, Spain
| | - Anna Vidal-Alabró
- Nephrology and Transplantation group (2017 SGR189), Institut d'Investigació Biomèdica (IDIBELL), Hospital Universitari de Bellvitge, Barcelona, Spain
| | - Miquel Hueso
- Nephrology and Transplantation group (2017 SGR189), Institut d'Investigació Biomèdica (IDIBELL), Hospital Universitari de Bellvitge, Barcelona, Spain
| | - Pere Fontova
- Nephrology and Transplantation group (2017 SGR189), Institut d'Investigació Biomèdica (IDIBELL), Hospital Universitari de Bellvitge, Barcelona, Spain
| | - Oriol Bestard
- Nephrology and Transplantation group (2017 SGR189), Institut d'Investigació Biomèdica (IDIBELL), Hospital Universitari de Bellvitge, Barcelona, Spain
| | - Ines Rama
- Nephrology and Transplantation group (2017 SGR189), Institut d'Investigació Biomèdica (IDIBELL), Hospital Universitari de Bellvitge, Barcelona, Spain
| | - Joan Torras
- Nephrology and Transplantation group (2017 SGR189), Institut d'Investigació Biomèdica (IDIBELL), Hospital Universitari de Bellvitge, Barcelona, Spain
| | - Josep M Grinyó
- Nephrology and Transplantation group (2017 SGR189), Institut d'Investigació Biomèdica (IDIBELL), Hospital Universitari de Bellvitge, Barcelona, Spain
| | - Pedro Alía-Ramos
- Biochemistry Department, IDIBELL, Hospital Universitari de Bellvitge, Barcelona, Spain
| | - Josep Maria Cruzado
- Nephrology and Transplantation group (2017 SGR189), Institut d'Investigació Biomèdica (IDIBELL), Hospital Universitari de Bellvitge, Barcelona, Spain
| | - Nuria Lloberas
- Nephrology and Transplantation group (2017 SGR189), Institut d'Investigació Biomèdica (IDIBELL), Hospital Universitari de Bellvitge, Barcelona, Spain
| |
Collapse
|
9
|
Schwertz H, Rondina MT. Cdkn2a
Orchestrates Platelet Production and Reactivity in Atherosclerosis. ACTA ACUST UNITED AC 2016; 9:203-5. [DOI: 10.1161/circgenetics.116.001479] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Hansjörg Schwertz
- From the Molecular Medicine Program (H.S., M.T.R.), Departments of Internal Medicine and Surgery (M.T.R.), and Division of Vascular Surgery (H.S.), University of Utah, Salt Lake City; and Department of Internal Medicine, George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, UT (M.T.R.)
| | - Matthew T. Rondina
- From the Molecular Medicine Program (H.S., M.T.R.), Departments of Internal Medicine and Surgery (M.T.R.), and Division of Vascular Surgery (H.S.), University of Utah, Salt Lake City; and Department of Internal Medicine, George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, UT (M.T.R.)
| |
Collapse
|